Scientists use radioactive tracer to follow new HIV Drug's path in the body

NCT ID NCT07636928

Recruiting now Knowledge-focused Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early-phase study will give 9 healthy adults a single dose of the experimental HIV drug VH4524184, plus a tiny radioactive version to track it. Researchers will measure how much of the drug gets into the blood, how it's broken down, and how it leaves the body through urine and stool. The goal is to learn the drug's basic behavior, not to test if it works against HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VH4524184
What this could lead to: If successful, this study will help researchers understand how VH4524184 moves through the body, which is a key step toward developing a new HIV treatment.
What could go wrong: This is a very early, small study in healthy people, not those with HIV. It only looks at how the drug is processed, not whether it works against the virus. The radioactive tracer is safe at these levels but adds complexity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.